Personalized Cancer Immunotherapy Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY THERAPY TYPE

1. 5.1. Introduction

2. 5.2. Immune Checkpoint Inhibitors

3. 5.3. CAR-T Cell Therapy

4. 5.4. T-Cell Receptor (TCR) Therapy

5. 5.5. Tumor-Infiltrating Lymphocytes (TIL) Therapy

6. 5.6. Cancer Vaccines (Personalized / Neoantigen-Based)

7. 5.7. Monoclonal Antibodies

8. 5.8. Cytokine-Based Therapies

6. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY CANCER TYPE

1. 6.1. Introduction

2. 6.2. Lung Cancer

3. 6.3. Breast Cancer

4. 6.4. Colorectal Cancer

5. 6.5. Melanoma

6. 6.6. Prostate Cancer

7. 6.7. Hematological Malignancies

8. 6.8. Others

7. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY END USER

1. 7.1. Introduction

2. 7.2. Hospitals

3. 7.3. Cancer Treatment Centers

4. 7.4. Research Institutes

5. 7.5. Specialty Clinics

8. PERSONALIZED CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. F. Hoffmann-La Roche Ltd.

2. 10.2. Bristol-Myers Squibb Company

3. 10.3. Merck & Co., Inc.

4. 10.4. AstraZeneca plc

5. 10.5. Pfizer Inc.

6. 10.6. Novartis AG

7. 10.7. Amgen Inc.

8. 10.8. Eli Lilly and Company

9. 10.9. Johnson & Johnson

10. 10.10. AbbVie Inc.

11. 10.11. Moderna, Inc.

12. 10.12. BioNTech SE

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations